Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial

McDermott, 1952, Isonicotinic acid hydrazide in tuberculosis in man, Trans Assoc Am Physicians, 65, 191 Heifets, 1991, Comparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium and Mycobacterium tuberculosis, Am Rev Respir Dis, 143, 268, 10.1164/ajrccm/143.2.268 Mitchison, 1998, Basic concepts in the chemotherapy of tuberculosis, 15 Jindani, 1980, The early bactericidal activity of drugs in patients with pulmonary tuberculosis, Am Rev Respir Dis, 121, 939 Jindani, 2003, Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days, Am J Respir Crit Care Med, 167, 1348, 10.1164/rccm.200210-1125OC Grosset, 1992, Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice, Antimicrob Agents Chemother, 36, 548, 10.1128/AAC.36.3.548 Almeida, 2009, Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis, Antimicrob Agents Chemother, 53, 4178, 10.1128/AAC.00830-09 Rockwood, 2017, Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis, Clin Infect Dis, 64, 1350, 10.1093/cid/cix158 Grosset, 2012, Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide, Proc Natl Acad Sci USA, 109, 15001, 10.1073/pnas.1203636109 Mitchison, 1992, Understanding the chemotherapy of tuberculosis—current problems, J Antimicrob Chemother, 29, 477, 10.1093/jac/29.5.477 van der Heijden, 2017, Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa, Int J Tuberc Lung Dis, 21, 670, 10.5588/ijtld.16.0843 Jenkins, 2011, Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994–2009, PLoS One, 6, 10.1371/journal.pone.0022927 Manson, 2017, Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance, Nat Genet, 49, 395, 10.1038/ng.3767 O'Donnell, 2018, Isoniazid monoresistance: a precursor to multidrug-resistant tuberculosis?, Ann Am Thorac Soc, 15, 306, 10.1513/AnnalsATS.201711-885ED Fregonese, 2018, Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis, Lancet Respir Med, 6, 265, 10.1016/S2213-2600(18)30078-X Gilpin, 2007, Critical appraisal of current recommendations and practices for tuberculosis sputum smear microscopy, Int J Tuberc Lung Dis, 11, 946 Zvada, 2012, Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine, Antimicrob Agents Chemother, 56, 4471, 10.1128/AAC.00404-12 Denti, 2015, Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto, South Africa, Antimicrob Agents Chemother, 60, 1234, 10.1128/AAC.02051-15 Kwara, 2016, Pharmacokinetics of first-line antituberculosis drugs using WHO revised dosage in children with tuberculosis with and without HIV coinfection, J Pediatric Infect Dis Soc, 5, 356, 10.1093/jpids/piv035 Donald, 2008, The early bactericidal activity of anti-tuberculosis drugs: a literature review, Tuberculosis (Edinb), 88, S75, 10.1016/S1472-9792(08)70038-6 Diacon, 2010, Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents, Eur J Clin Microbiol Infect Dis, 29, 1561, 10.1007/s10096-010-1043-7 Donald, 1997, The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis, Am J Respir Crit Care Med, 156, 895, 10.1164/ajrccm.156.3.9609132 Diacon, 2012, 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial, Lancet, 380, 986, 10.1016/S0140-6736(12)61080-0 Diacon, 2014, The early bactericidal activity of antituberculosis drugs, Expert Rev Anti Infect Ther, 12, 223, 10.1586/14787210.2014.870884 Blumberg, 2003, American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis, Am J Respir Crit Care Med, 167, 603, 10.1164/rccm.167.4.603 Mitchison, 1986, Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis, Am Rev Respir Dis, 133, 423 1987, Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis, Am Rev Respir Dis, 136, 1339, 10.1164/ajrccm/136.6.1339 Gegia, 2017, Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis, Lancet Infect Dis, 17, 223, 10.1016/S1473-3099(16)30407-8 Chigutsa, 2013, A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture, Antimicrob Agents Chemother, 57, 789, 10.1128/AAC.01876-12 Chigutsa, 2015, Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis, Antimicrob Agents Chemother, 59, 38, 10.1128/AAC.03931-14 De Jager, 2017, Time trends in sputum mycobacterial load and two-day bactericidal activity of isoniazid-containing antituberculosis therapies, Antimicrob Agents Chemother, 61, e02088, 10.1128/AAC.02088-16 Dean, 2017, Epidemiology of drug-resistant tuberculosis, 209 Cohen, 2015, Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from KwaZulu-Natal, PLoS Med, 12, 10.1371/journal.pmed.1001880